|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 703.26 USD | -2.10% |
|
-6.25% | -1.27% |
| Capitalization | 72.15B 62.11B 58.31B 54.2B 99.91B 6,505B 109B 679B 263B 3,071B 271B 265B 11,252B | P/E ratio 2025 * |
17x | P/E ratio 2026 * | 17.8x |
|---|---|---|---|---|---|
| Enterprise value | 65.58B 56.45B 53B 49.27B 90.81B 5,913B 99.07B 618B 239B 2,792B 246B 241B 10,227B | EV / Sales 2025 * |
4.62x | EV / Sales 2026 * | 4.21x |
| Free-Float |
77.36% | Yield 2025 * |
0.52% | Yield 2026 * | 0.56% |
Last Transcript: Regeneron Pharmaceuticals, Inc.
| 1 day | -2.10% | ||
| 1 week | -6.25% | ||
| Current month | -9.86% | ||
| 1 month | +6.95% | ||
| 3 months | +25.93% | ||
| 6 months | +42.59% | ||
| Current year | -1.27% |
| 1 week | 701.74 |  | 744.22 |
| 1 month | 651.38 | | 790.98 |
| Current year | 476.49 | | 790.98 |
| 1 year | 476.49 | | 791.49 |
| 3 years | 476.49 | | 1,211.2 |
| 5 years | 441 | | 1,211.2 |
| 10 years | 271.37 | | 1,211.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 65 | 2000-12-31 | |
| Chief Executive Officer | 72 | 1988-01-07 | |
| Director of Finance/CFO | 54 | 2024-02-04 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 72 | 2023-06-08 | |
Michael Brown
BRD | Director/Board Member | 84 | 1991-05-31 |
Joseph Goldstein
BRD | Director/Board Member | 84 | 1991-05-31 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.10% | -6.25% | -9.61% | -8.12% | 73.7B | |
| -1.28% | -0.13% | -34.87% | -38.62% | 58.94B | |
| +0.28% | +3.59% | +33.94% | +242.06% | 54.7B | |
| -0.73% | +62.90% | +62.90% | +62.90% | 51.57B | |
| -0.47% | +1.50% | +14.36% | -37.59% | 26.6B | |
| -1.99% | -10.60% | +114.58% | +160.16% | 20.25B | |
| -5.68% | -5.23% | +27.37% | +14.97% | 20.13B | |
| +0.33% | -15.50% | +49.67% | +1,035.07% | 16.58B | |
| +0.81% | +3.43% | +157.87% | +678.20% | 14.19B | |
| -0.04% | -.--% | +55.97% | +154.53% | 14.02B | |
| Average | -1.08% | -2.00% | +47.22% | +226.36% | 35.07B | |
| Weighted average by Cap. | -1.14% | -1.92% | +26.92% | +128.62% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 14.2B 12.23B 11.48B 10.67B 19.67B 1,281B 21.46B 134B 51.79B 605B 53.31B 52.17B 2,215B | 15.1B 13B 12.21B 11.35B 20.91B 1,362B 22.82B 142B 55.07B 643B 56.69B 55.47B 2,355B |
| Net income | 4.41B 3.8B 3.56B 3.31B 6.11B 398B 6.66B 41.52B 16.08B 188B 16.55B 16.2B 688B | 4.03B 3.47B 3.26B 3.03B 5.58B 364B 6.09B 37.97B 14.7B 172B 15.13B 14.81B 629B |
| Net Debt | -6.57B -5.66B -5.31B -4.94B -9.1B -592B -9.93B -61.87B -23.96B -280B -24.66B -24.13B -1,025B | -8.63B -7.43B -6.98B -6.49B -11.96B -778B -13.04B -81.3B -31.48B -368B -32.4B -31.71B -1,346B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-08 | 703.26 $ | -2.10% | 1,005,902 |
| 25-12-05 | 718.36 $ | -0.61% | 798,452 |
| 25-12-04 | 722.80 $ | -0.12% | 1,067,133 |
| 25-12-03 | 723.67 $ | -2.47% | 1,238,676 |
| 25-12-02 | 742.00 $ | -1.08% | 924,677 |
Delayed Quote Nasdaq, December 08, 2025 at 04:00 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- REGN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition